Mounjaro vs. Ozempic: A Side-by-Side Comparison
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both popular GLP-1 class medications but they work differently. Here is an honest comparison.
How Each Works
While both Mounjaro and Ozempic belong to the broader category of incretin-based therapies, they have a key mechanistic difference:
Ozempic (Semaglutide): A GLP-1 receptor agonist. It works by mimicking the glucagon-like peptide-1 hormone, which helps regulate blood sugar and appetite through a single receptor pathway.
Mounjaro (Tirzepatide): A dual GIP and GLP-1 receptor agonist. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor AND the GLP-1 receptor. This dual action may provide enhanced effects on metabolism and appetite through two complementary pathways.
The addition of GIP receptor activation in Mounjaro is thought to contribute to its particularly robust effects, though the exact contributions of each pathway are still being studied.
FDA-Approved Uses
Ozempic: FDA-approved for the treatment of type 2 diabetes mellitus in adults. It also has FDA approval for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Mounjaro: FDA-approved for the treatment of type 2 diabetes mellitus in adults. It was initially approved in 2022 for diabetes, and Zepbound (also tirzepatide) was later approved specifically for chronic weight management.
Both medications are used off-label for weight management in some cases, though Wegovy (semaglutide) and Zepbound (tirzepatide) are the respective formulations with FDA approval specifically for weight management.
Dosing and Administration
Both medications are administered as weekly subcutaneous injections using pre-filled pens:
Ozempic Dosing: - Starting: 0.25 mg weekly for 4 weeks - Escalation: 0.5 mg, then 1 mg - Maximum: 2 mg weekly
Mounjaro Dosing: - Starting: 2.5 mg weekly for 4 weeks - Escalation: 5 mg, 7.5 mg, 10 mg, 12.5 mg - Maximum: 15 mg weekly
Mounjaro has more dose options, allowing for more gradual titration and customization based on individual response and tolerability.
Side Effect Profiles
Affiliate Disclosure: The following is a sponsored recommendation.
Orderly Wellness
Orderly Wellness is a telehealth platform connecting patients with licensed healthcare providers who specialize in metabolic health and GLP-1 medication management.
- Licensed providers available in most U.S. states
- Comprehensive metabolic health evaluations
- Ongoing care team support throughout your treatment
Consultation does not guarantee a prescription. Eligibility is determined by a licensed provider.
Both medications share similar gastrointestinal side effects, as these are characteristic of the GLP-1 class:
Common side effects for both: - Nausea - Vomiting - Diarrhea - Constipation - Abdominal pain - Decreased appetite
Comparative tolerability: In clinical trials, the rates of gastrointestinal side effects were generally similar between the two medications, though direct head-to-head comparisons are limited. Both typically see improvement in side effects over time as the body adjusts.
Serious warnings: Both carry boxed warnings about the potential risk of thyroid C-cell tumors (based on animal studies) and should not be used in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Cost Comparison
Without insurance, both medications are similarly priced:
- Ozempic: Approximately $935/month - Mounjaro: Approximately $1,060/month
Actual out-of-pocket costs vary significantly based on insurance coverage, formulary placement, and manufacturer savings programs. Both companies offer savings cards that can substantially reduce costs for eligible patients with commercial insurance.
Which to Discuss with Your Doctor
The choice between Mounjaro and Ozempic depends on individual factors:
Consider Mounjaro if: - You are looking for the dual GIP/GLP-1 mechanism - You want more dosing flexibility - Your insurance formulary favors Mounjaro - You have tried GLP-1-only medications with limited success
Consider Ozempic if: - You need cardiovascular risk reduction (FDA-approved indication) - Your insurance formulary favors Ozempic - You prefer a medication with a longer track record - You have had good results with other semaglutide products
Bottom Line
Both Mounjaro and Ozempic are effective medications for type 2 diabetes management, with significant effects on blood sugar control and body weight. The key difference is Mounjaro's dual receptor mechanism, which may provide advantages for some patients.
Neither is inherently "better" — the right choice depends on your specific health needs, insurance coverage, and how your body responds. Your healthcare provider can help determine which medication, if either, is most appropriate for your situation.
This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
Related Articles
Ozempic vs. Wegovy: What's the Difference?
Both contain semaglutide, but Ozempic and Wegovy are FDA-approved for different conditions and come in different doses. Here is what you need to know.
Read articleUnderstanding GLP-1 Medications: A Complete Guide for 2025
A comprehensive, evidence-based guide to GLP-1 receptor agonists including semaglutide and tirzepatide — how they work, who qualifies, and what to expect.
Read article